TrialCurveNRG-HN004: reconstructed Kaplan–Meier curves
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Oncol. Author manuscript; Available in PMC 2025 Jan 13. |
|---|---|
| DOI | 10.1016/S1470-2045(24)00507-2 |
| Registry | NCT03258554 |
| Phase | Phase 2, Phase 3 |
| Conditions | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma |
| Interventions | Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration |
| Sponsor | National Cancer Institute (NCI) |
| Enrolment | 196 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival — Post-hoc analysis population
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Radiotherapy plus cetuximab 3.2 years; Radiotherapy plus durvalumab 2.2 years. Survival at 1 years: Radiotherapy plus cetuximab 71%; Radiotherapy plus durvalumab 64%. Hazard ratio Radiotherapy plus cetuximab vs Radiotherapy plus durvalumab 0.75 (95% CI 0.48–1.18).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Radiotherapy plus cetuximab | 63 | 26 | 3.2 |
| Radiotherapy plus durvalumab | 123 | 64 | 2.2 |
- Radiotherapy plus cetuximab vs Radiotherapy plus durvalumab: reconstructed HR 0.75 (95% CI 0.48–1.18)
Landmark survival (reconstructed)
| Time | Radiotherapy plus cetuximab | Radiotherapy plus durvalumab |
|---|---|---|
| 1 yr | 70.8% | 64.4% |
| 2 yr | 63.6% | 50.3% |
| 3 yr | 55.6% | 44.9% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.33, reconstructed 1.33 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- KEYNOTE-048 (Japanese subgroup, 5-year): Overall survival; Progression-free survival (PFS)
- CAPTAIN-1st: Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials